Lurbinectedin is a chemotherapy drug that has been approved by the FDA for the treatment of metastatic small cell lung cancer (SCLC) in patients who have previously received chemotherapy. The drug works by inhibiting the transcription process of cancer cells, which ultimately leads to cell death [1].

According to a study published in the Journal of Medical Economics, lurbinectedin is cost-effective as a second-line treatment in SCLC. The study found that the drug was associated with a lower cost per progression-free survival (PFS) month compared to current treatments [2].

Another study published in the Journal of Clinical Oncology found that lurbinectedin demonstrated a higher response rate and longer PFS compared to topotecan, a current second-line treatment for SCLC. The study also found that lurbinectedin had a manageable safety profile [3].

In conclusion, based on the provided sources, lurbinectedin appears to be more effective than current treatments for SCLC. It has demonstrated a higher response rate, longer PFS, and is cost-effective as a second-line treatment. However, it is important to note that further studies may be needed to fully evaluate the drug's effectiveness and safety profile.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.targetedonc.com/view/lurbinectedin-is-cost-effective-as-a-second-line-treatment-in-sclc
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/